Ziprasidone in the treatment of acute mania: A 12-week, placebo-controlled, haloperidol-referenced study

Journal of Psychopharmacology

Volumn 24, Issue 4, 2010, Pages 547-558

  Vieta, E ^a   Ramey, T ^b   Keller, D ^b   English, P A ^c   Loebel, A D ^d   Miceli, J ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c PFIZER INC   (United States)

^d Dainippon Sumitomo Pharma America Inc   (United States)

Author keywords

Bipolar; Depression; Haloperidol; Mania; Ziprasidone

Indexed keywords

HALOPERIDOL; PLACEBO; ZIPRASIDONE;

ACUTE DISEASE; ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BIPOLAR MANIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSTONIA; FEMALE; HEADACHE; HUMAN; HYPOKINESIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MUSCLE HYPOTONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT RESPONSE; TREMOR;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; INDIA; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIPERAZINES; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; RUSSIA; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77950396957     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108099418     Document Type: Article

References (32)

1. Allison, DB, Mentore, JL, Heo, M., Chandler, LP, Cappelleri, JC, Infante, MC, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696. (Pubitemid 29517559)
2. American Diabetes Association, American Psychiatry Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65: 267-272.
3. American Psychiatric Association (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 (4 Suppl.). 1-50. (Pubitemid 34274969)
4. Blier, P., Ward, NM (2003) Is there a role for 5-HT1A agonists in the treatment of depression ? Biol Psychiatry 53: 193-203. (Pubitemid 36135929)
5. Bourin, M., Lambert, O., Guitton, B. (2005) Treatment of acute mania- from clinical trials to recommendations for clinical practice. Hum Psychopharmacol 20: 15-26. (Pubitemid 40227641)
6. Brugue, E., Vieta, E. (2007) Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psychiatry 31: 275-282. (Pubitemid 44959242)
7. Casey, DE (2004) Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 65 (Suppl. 18). 27-35.
8. Daly, I. (1997) Mania. Lancet 349: 1157-1160.
9. Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20: 491-505.
10. Goff, DC, Posever, T., Herz, L., Simmons, J., Kletti, N., Lapierre, K., et al. (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18: 296-304.
11. Grunze, H., Kasper, S., Goodwin, G., Bowden, C., Baldwin, D., Licht, RW, et al. (2003) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part II: Treatment of mania. World J Biol Psychiatry 4: 5-13.
12. Hirsch, SR, Kissling, W., Bauml, J., Power, A., OConnor, R. (2002) A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 63: 516-523.
13. Keck J. r, P, Buffenstein, A., Ferguson, J., Feighner, J., Jaffe, W., Harrigan, EP, et al. (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 140: 173-184.
14. Keck Jr, PE (2005) Ziprasidone in bipolar mania: efficacy across patient subgroups. Presented at: American Psychiatric Association ; May 21-26, 2005, Atlanta, GA.
15. Keck Jr, PE, Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A., et al. (2003 a) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160: 1651-1658.
16. Keck Jr, PE, Versiani, M., Potkin, S., West, SA, Giller, E., Ice, K. (2003 b) Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 160: 741-748.
17. Kent, JM, Mathew, SJ, Gorman, JM (2002) Molecular targets in the treatment of anxiety. Biol Psychiatry 52: 1008-1030.
18. Khanna, S., Vieta, E., Lyons, B., Grossman, F., Eerdekens, M., Kramer, M. (2005) Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 187: 229-234.
19. McElroy, SL, Keck, PE, Stanton, SP, Tugrul, KC, Bennett, JA, Strakowski, SM (1996) A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 57: 142-146.
20. McIntyre, RS, Brecher, M., Paulsson, B., Huizar, K., Mullen, J. (2005) Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 15: 573-585.
21. Potkin, SG, Keck Jr, PE, Segal, S., Ice, K., English, P. (2005) Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 25: 301-310.
22. Reinares, M., Vieta, E., Colom, F., Martinez-Aran, A., Torrent, C., Comes, M., et al. (2006) What really matters to bipolar patients caregivers: sources of family burden. J Affective Disord 94: 157-163.
23. Seeger, TF, Seymour, PA, Schmidt, AW, Zorn, SH, Schulz, DW, Lebel, LA, et al. (1995) Ziprasidone (CP-88,059). a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275: 101-113.
24. Segal, J., Berk, M., Brook, S. (1998) Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 21: 176-180.
25. Simpson, GM, Weiden, P., Pigott, T., Murray, S., Siu, CO, Romano, SJ (2005) Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 162: 1535-1538. (Pubitemid 41105572)
26. Smulevich, AB, Khanna, S., Eerdekens, M., Karcher, K., Kramer, M., Grossman, F. (2005) Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 15: 75-84. (Pubitemid 39574402)
27. Tohen, M., Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, Azorin, JM, Vieta, E., Hardy-Bayle, MC, et al. (2003) A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 60: 1218-1226. (Pubitemid 37494075)
28. Tohen, M., Sanger, TM, McElroy, SL, Tollefson, GD, Chengappa, KN, Daniel, DG, et al. (1999) Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 156: 702-709.
29. Vieta, E. (2003) Atypical antipsychotics in the treatment of mood disorders. Curr Opin Psychiatry 16: 23-27. (Pubitemid 36092328)
30. Vieta, E., Bourin, M., Sanchez, R., Marcus, R., Stock, E., McQuade, R., et al. (2005 a) Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 187: 235-242. (Pubitemid 41306104)
31. Vieta, E., Mullen, J., Brecher, M., Paulsson, B., Jones, M. (2005 b) Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 21: 923-934. (Pubitemid 40896240)
32. Woods, SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663-667.